CLX

Business Profile & Competitive Position

The Clorox Company sits in the Consumer Defensive sector, specifically the Household & Personal Products industry. It manufactures and markets a mix of consumer staples—Clorox bleach, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, and Burt’s Bees—and professional health/hygiene products under Purell, CloroxPro, and Clorox Healthcare. That brand lineup gives the company broad shelf presence in cleaning, food, pet care, and personal care, which tends to generate recurring demand. However, the data also reveal where the moat may be weaker or at least more complicated than the brand names alone suggest.

Net margin is 8.7%. That is a respectable mid-single-digit-to-high-single-digit consumer staples margin, but it does not point to extraordinary pricing power. ROE is reported at –1,893.5%, which is the far more important figure. A negative ROE of that magnitude is not a sign of poor operating returns in the normal sense; it almost always reflects a deeply negative or near-zero shareholders’ equity base, often produced by aggressive share buybacks, accumulated deficits, or a leveraged balance sheet. In Clorox’s case it means the textbook ROE ratio is distorted and should not be used as a standalone quality signal. What the negative equity-like backdrop does flag is balance-sheet risk: if liabilities materially exceed assets, the company has a thinner equity cushion and less room to absorb a large write-down or sustained earnings drop.

The fiscal 2026 10-K also highlights heavy customer concentration. Walmart alone represented 26% of consolidated net sales, and the five largest customers made up about half of total net sales. In that kind of retail environment, even strong brands face pricing discussions and shelf-space pressure from a handful of buyers, which can limit margin expansion over time.

Financial Posture

As of the snapshot, Clorox carried a market capitalization of $10.0 billion, traded at a P/E of 17.2, and posted a beta of 0.54. The low beta fits the defensive label: the stock historically moves a little more than half as much as the overall market. The P/E of 17.2 sits in the middle-to-reasonable zone for large-cap household products, though valuation has to be read against the company’s recent earnings compression.

Net margin of 8.7% is the headline profitability metric; it shows Clorox still converts sales into profit, but the negative ROE distorts return analysis. Investors should treat this as a leveraged, capital-return-heavy capital structure rather than a profitable firm with negative returns. Any financial-posture review should therefore pair the 8.7% margin with debt, pension, buyback, and equity levels from the full filings rather than relying on the P/E alone.

Strategic Priorities & Outlook

Clorox’s most recent 10-K describes the company as a multinational manufacturer with fiscal 2026 net sales of $6.7 billion, roughly 9,200 employees, operations in about 25 countries, and sales in roughly 95 markets. In April 2026 the company closed the acquisition of GOJO Industries, which expands the health and hygiene portfolio and strengthens the business-to-business channel through the Purell brand.

Management’s stated framework is the IGNITE strategy, built around four choices: fueling long-term profitable growth, innovating consumer experiences, reimagining how the company and its people work, and continuously evolving the product portfolio. Operationally, that translates into three near-term priorities that show up in the filing:

• Complete and optimize a new enterprise resource planning (ERP) system and broader digital transformation, with the goal of long-term efficiencies across supply chain, digital commerce, innovation, and brand building.
• Invest in strong brands, strategic digital capabilities, and a streamlined operating model to build a more resilient company and deliver consistent, profitable growth.
• Advance health and hygiene expansion and portfolio optimization, including integrating the GOJO acquisition and growing professional and institutional markets.

The filing also notes fiscal 2026 was a difficult year: organic sales and earnings declined, and diluted EPS fell 26%. Management attributes part of the drop to macroeconomic headwinds and to ERP transition timing that had pulled some sales into fiscal 2025. Another structural change is the expiration of the Glad bags and wraps joint venture with P&G on January 31, 2026. Clorox purchased P&G’s 20% interest, and Glad retained core intellectual property licenses on a royalty-free basis. The GOJO integration and the ERP rollout are therefore the two operational threads that will likely dominate fiscal 2027 results.

Macro & Geopolitical Exposure

Because Clorox is classified in Household & Personal Products, its macro exposure follows the typical consumer-defensive checklist rather than a cyclical one. Demand for bleach, cat litter, trash bags, and cleaning supplies is relatively stable, but the business is not immune to larger forces.

Input costs matter: resins and plastics for Glad bags, chemicals and packaging for cleaning products, and charcoal and pet-care inputs can swing with commodity markets. Freight, warehousing, and labor costs also feed directly into margins. Currency risk is real given sales in about 95 markets; a stronger U.S. dollar reduces the value of overseas revenue when translated back. Regulatory exposure is meaningful as well, since disinfectant claims fall under EPA oversight, advertising under FTC scrutiny, and product safety/packaging under state and federal rules. Finally, the sector faces ongoing private-label competition and retailer consolidation, which puts pressure on branded pricing.

Recent Developments

The most recent headlines show mixed institutional attention around the name:

• [2026-09-21] The Clorox Company $CLX Shares Bought by MAC Alpha Capital Management LP (defenseworld.net)
• [2026-09-18] Baird Financial Group Inc. Cuts Position in The Clorox Company $CLX (defenseworld.net)

Those two filings point in different directions—one new buyer increasing its stake, one existing holder trimming. That divergence fits a stock under fundamental pressure rather than a clear consensus move.

• [2026-09-19] These 6 Massive Dividend Yields May Be Too Good to Be True (247wallst.com)

A headline flagging “too good to be true” dividend yields often signals investor concern about payout sustainability; for a consumer-staples name it means the market is questioning whether the current yield can be funded from depressed earnings. That is a data point worth cross-checking against free-cash-flow coverage, but it is not by itself a call on the dividend.

• [2026-09-17] ADRNY vs. CLX: Which Stock Should Value Investors Buy Now? (zacks.com)

The comparison article, published by Zacks, simply reflects that value-oriented screens are comparing Clorox against other household-products names. None of these headlines amount to a directional verdict; collectively they show the stock is being actively reassessed by institutional holders and financial media.

Earnings Behavior & Post-Earnings Drift

Over the last eight reported quarters, Clorox beat the estimate six times, for a beat rate of 75.0%, with an average earnings surprise of 9.6%. The average five-day price move after earnings across those quarters was +1.67%, classified as an “up” drift. That suggests the stock has historically absorbed headline results and then drifted modestly higher in the days following the report, even when the initial reaction was negative.

The most recent four quarters illustrate that pattern clearly:

• 2026-08-03: actual EPS $1.66 vs. estimate $1.64 (+1.2% surprise, beat). Next-day move: +6.52%; 5-day move: +9.61%.
• 2026-04-30: actual EPS $1.64 vs. estimate $1.55 (+5.8% surprise, beat). Next-day move: –9.67%; 5-day move: –4.49%.
• 2026-02-03: actual EPS $1.39 vs. estimate $1.43 (–2.8% surprise, miss). Next-day move: +2.43%; 5-day move: +5.63%.
• 2025-11-03: actual EPS $0.85 vs. estimate $0.818 (+3.9% surprise, beat). Next-day move: +1.17%; 5-day move: –4.08%.

The April 2026 quarter is the standout: a beat on EPS was followed by a 9.67% single-day drop, indicating the market’s real expectation—or the unofficial consensus—was focused on revenue, guidance, or margin commentary rather than the EPS print. The February miss, by contrast, saw a positive five-day drift of 5.63%, showing that post-earnings price action is not purely tied to the beat/miss label.

The next scheduled report is November 3, 2026 after the close, with a consensus EPS estimate of $1.11. The stock’s current price is $83.10, RSI is 21.5, and the 50-day EMA is $96.17. The RSI below 30 and the price sitting well under the 50-day moving average describe a technically oversold setup heading into the print, but that is descriptive, not predictive.

For a deeper dive into where institutional analysts and smart money currently stand on Clorox—including consensus recommendations, target dispersion, and how the November 2026 estimate compares with the company’s own guidance—look at the full institutional verdict rather than relying on any single headline or pre-report technical reading.